In one paragraphArticle in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
16 authors.
Elizabeth AbrahamDepartment of Cardiovascular Sciences, Aging + Cardiovascular Discovery Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.ORCID 0000-0002-2143-6597 Thomas RouleRaymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.ORCID 0000-0001-6661-9357 Aidan DouglasDepartment of Cardiovascular Sciences, Aging + Cardiovascular Discovery Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.
Emily MegillDepartment of Cardiovascular Sciences, Aging + Cardiovascular Discovery Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.
Olivia M PericakDepartment of Cardiovascular Sciences, Aging + Cardiovascular Discovery Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.
Jordan E HoweDepartment of Cardiovascular Sciences, Aging + Cardiovascular Discovery Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.ORCID 0009-0009-9172-7830 Carmen Choya-FocesDepartment of Cardiovascular Sciences, Aging + Cardiovascular Discovery Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.ORCID 0000-0001-5804-1700 Joanne F GarbinciusDepartment of Cardiovascular Sciences, Aging + Cardiovascular Discovery Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.ORCID 0000-0002-4334-6445 Henry M CohenDepartment of Cardiovascular Sciences, Aging + Cardiovascular Discovery Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.ORCID 0000-0002-2172-2008 Paula Roig-FlórezDepartment of Cardiovascular Sciences, Aging + Cardiovascular Discovery Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.
Mikel ZubillagaDepartment of Cardiovascular Sciences, Aging + Cardiovascular Discovery Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.
Mark D AndrakeMolecular Modeling Facility, Program in Cancer Signaling and Microenvironment, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.ORCID 0000-0003-2957-4350 Seonhee KimDepartment of Neural Sciences, Center for Neural Development and Repair, Temple University, Lewis Katz School of Medicine, Philadelphia, PA, 19140, USA.ORCID 0000-0003-4559-6381 John W ElrodDepartment of Cardiovascular Sciences, Aging + Cardiovascular Discovery Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.ORCID 0000-0003-3925-2224 Naiara AkizuRaymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.ORCID 0000-0001-9222-6960 Conchi EstarasDepartment of Cardiovascular Sciences, Aging + Cardiovascular Discovery Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA. conchi.estaras@temple.edu.ORCID 0000-0002-2600-5841 Funding
WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Eric Andrew Ross · 1985 to 2026
$138.8MTumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2MIntegrative Cardiovascular PathophysiologyT32HL091804 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI ELROD, JOHN WILLIAM · 2008 to 2024
$4.5MThe role of EZH1 in neuronal differentiation and neurological disordersR01NS119699 · NINDS · CHILDREN'S HOSP OF PHILADELPHIA · PI Naiara Akizu · 2022 to 2026
$2.8MThe Role of Hippo-Yap1 Signaling in Germ-layer SpecificationR01HD106969 · NICHD · TEMPLE UNIV OF THE COMMONWEALTH · PI Concepcion Estaras · 2022 to 2026
$2.1MMolecular Biology and Genetics: Signaling, Epigenetics and Genome MaintenanceT32GM142606 · NIGMS · TEMPLE UNIV OF THE COMMONWEALTH · PI Xavier Grana, Kelly A Whelan · 2021 to 2026
$1.5MInvestigating the role of YAP1 in blood cell specificationF31HD113419 · NICHD · TEMPLE UNIV OF THE COMMONWEALTH · PI ABRAHAM, ELIZABETH · 2024 to 2025
$47kNCI NIH HHS P30 CA006927NCI NIH HHS P30 CA030199NHLBI NIH HHS T32 HL091804NICHD NIH HHS F31 HD113419NICHD NIH HHS R01 HD106969NIGMS NIH HHS T32 GM142606NIH Cancer Center Support Grant P30 CA006927NIH Cancer Center Support P30 CA030199NIH/NGMS GM142606NIH/NHLBI 5T32HL091804NIH/NICHD F31HD113419NIH/NICHD HD106969NIH/NINDS R01NS119699NINDS NIH HHS R01 NS119699
6 · The paper itselfAbstract
YAP1 signaling is essential for development but its specific roles in early embryogenesis remain poorly understood. To shed light on this, we analyze YAP1's role in regulating the pluripotency of the mammalian epiblast, using scRNAseq approaches. Conditional deletion of Yap1 in the mouse epiblast (Sox2-Cre) alters the expression of signaling genes, including Nodal, Wnt3, and Fgf8. Accordingly, Yap1 loss leads to enhanced differentiation of the epiblast toward primitive streak lineages, as evidenced by the upregulation of T/Brachyury and Eomes genes. A proximity labeling assay in human pluripotent stem cells, followed by biochemical assays and molecular modeling predictions, reveals that YAP1 cooperates with QSER1 protein to regulate lineage genes. Our analysis shows that YAP1:TEAD4 enhancers recruit QSER1 to prevent RNA Polymerase II recruitment. QSER1 depletion, similar to YAP1, increases NODAL gene expression and leads to hyperactive NODAL signaling during human embryonic stem cells differentiation. Overall, our findings define a role of YAP1 in the epiblast in vivo and uncover an interplay with QSER1 controlling the activity of developmental signaling pathways in pluripotent cells.
Indexed as
Adaptor Proteins, Signal TransducingGerm LayersPhosphoproteinsSignal TransductionAnimalsCell Cycle ProteinsCell DifferentiationEmbryonic DevelopmentGene Expression Regulation, DevelopmentalHumansMiceNodal ProteinPluripotent Stem CellsTranscription FactorsYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingCell Cycle ProteinsNodal ProteinPhosphoproteinsTranscription FactorsYAP1 protein, humanYap1 protein, mouseYAP-Signaling ProteinsEpiblastNodal SignalingPluripotencyQSER1YAP1
Identifiers
PMID41888256
PMCPMC13172546
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390